Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06206135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

StatusRecruiting
PhaseNot specified
SponsorLG Chem
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Kyowa Kirin Korea Co., Ltd. to LG Chem
    • Enrollment target: 100 to 172
    • Primary completion date: Dec 31, 2025 to Feb 28, 2028
    • Study completion date: Dec 31, 2025 to Dec 31, 2028
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
LG Chem
13 trials monitored
See 1 trial at risk
The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.
Trial Details
NCT Number NCT06206135
Lead Sponsor LG Chem
Conditions
(from sponsor)		 Hyperphosphatemia
Related terms Hyperphosphatemia
Enrollment 172 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov